ImmunityBio
  • ANKTIVA®
  • Clinical Trials
    • Find a Trial
    • Become a Trial
      Investigator
    • License our Cells
  • Science
    • Platforms
    • Pipeline
    • Expanded Access
    • Research
  • Approach
    • Patients
    • Trial Investigators
    • Researchers
  • Condition
    • Bladder Cancer
    • Glioblastoma
    • HIV
    • Lynch / Colon Cancer
    • Non-Hodgkin Lymphoma
    • Human Papillomavirus
    • Non-Small Cell Lung Cancer
  • Company
    • About Us
    • Investors
    • News and Events
    • Contact
  • Careers
  • Founder’s Vision
    • Cancer Moonshot 2020
    • Childhood Cancer – Sen. McCain
    • Cancer Moonshot Announcement
    • Formation of ImmunityBio
Select Page

Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Sep 15, 2023 | Events

Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting Date: Nov. 1-5 Location: San Diego Convention Center, San Diego, Calif. Conference Event...

Bladder Cancer Advocacy Network’s (BCAN) Annual Bladder Cancer Summit for Patients and Families

Sep 15, 2023 | Events

Bladder Cancer Advocacy Network’s (BCAN) Annual Bladder Cancer Summit for Patients and Families Date: Oct. 27-28 2023 Location: Nashville, Tenn. Conference Event...

United Nations “Unveiling the Future of Intelligent Health in Africa”

Aug 15, 2023 | Events

United Nations “Unveiling the Future of Intelligent Health in Africa” panel Date: Sept. 21, 2023, 4:00pm EST Location: New York Recording of the Sept. 21, 2023 GABI panel discussion with Dr....

Jefferies Global Healthcare Conference

Jun 5, 2023 | Events

Jefferies Global Healthcare ConferenceDate: Jun 7, 2023 10:00 AM EDTLocation: Marriott Marquis, New...

2023 ASCO Annual Meeting

Apr 17, 2023 | Events

2023 ASCO Annual MeetingDate: June 2-6, 2023Location: Chicago, ILBooth no. 26097Conference Event...

American Urological Association (AUA) Annual Meeting

Apr 13, 2023 | Events

2023 American Urological Association (AUA) Annual MeetingDate: April 28-May 1, 2023Location: Chicago, ILBooth no. 3807Conference Event...
« Older Entries
Next Entries »

Recent Posts

  • ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months
  • ImmunityBio Reports Third-Quarter 2024 Financial Results
  • First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma
  • Jefferies London Healthcare Conference
  • ImmunityBio to Participate in the Jefferies London Healthcare Conference
 

Quicklinks

  • Pipeline
  • Careers
  • News and Events
  • Investors
  • Contact

Follow Us

  •  Facebook
  •  X
  •  LinkedIn

Legal

  • Privacy Policy
  • Legal Notice
  • Patent Notice
  • How-To-Use-Accessibe

© 2024 ImmunityBio, Inc. All Rights Reserved.

A member of the NantWorks ecosystem of companies

’ImmunityBio’, ‘ImmunityBio Care’, 'Anktiva’, ‘ThAnktiva’, ‘haNK’, ‘taNK’, ‘ceNK’, ‘NK-92’, ‘Nant Cancer Vaccine’, ‘NANT 001’, ‘NANT XL’, ‘NANT 001 and Design’, ‘QUILT’, ‘Outsmart Your Disease’, ‘Smart Therapies for Difficult Diseases’, ‘Nantkwest’, ‘VivaBioCell’, and ‘Infacell’ are trademarks or registered trademarks of ImmunityBio, Inc., its subsidiaries and affiliates.

The Natural Killer Cell platform consists of investigational agents that are restricted by federal law to investigational use only.

The Natural Killer Cell platform is being investigated in multiple clinical trials across tumor sites.

The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.

Sitemap